Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Depreciation & Amortization (CF) (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Depreciation & Amortization (CF) for 7 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 2.26% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.3 million through Dec 2025, up 12.75% year-over-year, with the annual reading at $8.3 million for FY2025, 12.75% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $2.0 million at Kymera Therapeutics, down from $2.1 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $2.1 million in Q3 2025, with the low at $485000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.2 million, with a median of $893000.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 123.01% in 2024, then rose 2.26% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $689000.0 in 2021, then increased by 18.72% to $818000.0 in 2022, then grew by 8.92% to $891000.0 in 2023, then surged by 123.01% to $2.0 million in 2024, then rose by 2.26% to $2.0 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $2.0 million, $2.1 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.